The TP53 gene polymorphisms and survival of sporadic breast cancer patients

被引：7
作者：
Bisof, V. [1 ]
Salihovic, M. Pericic [2 ]
Narancic, N. Smolej [2 ]
Skaric-Juric, T. [2 ]
Jakic-Razumovic, J. [3 ]
Janicijevic, B. [2 ]
Rudan, P. [2 ]
机构：
[1] Clin Hosp Ctr Zagreb, Dept Oncol, Zagreb 10000, Croatia
[2] Inst Anthropol Res, Zagreb 10000, Croatia
[3] Clin Hosp Ctr Zagreb, Dept Pathol, Zagreb 10000, Croatia
来源：
MEDICAL ONCOLOGY | 2012年 / 29卷 / 02期
关键词：
Breast cancer; Survival; Polymorphisms; TP53; gene; Chemotherapy; CODON-72 ARGININE ALLELE; IN-VITRO; P53; VARIANTS; CHEMOTHERAPY; MUTATIONS; GENOTYPE; RISK;
D O I：
10.1007/s12032-011-9875-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The TP53 gene polymorphisms, Arg72Pro and PIN3 (+16 bp), can have prognostic and predictive value in different cancers including breast cancer. The aim of the present study is to investigate a potential association between different genotypes of these polymorphisms and clinicopathological variables with survival of breast cancer patients in Croatian population. Ninety-four women with sporadic breast cancer were retrospectively analyzed. Median follow-up period was 67.9 months. The effects of basic clinical and histopathological characteristics of tumor on survival were tested by Cox's proportional hazards regression analysis. The TNM stage was associated with overall survival by Kaplan-Meier analysis, univariate, and multivariate Cox's proportional hazards regression analysis, while grade was associated with survival by Kaplan-Meier analysis and univariate Cox's proportional hazards regression analysis. Different genotypes of the Arg72Pro and PIN3 (+16 bp) polymorphisms had no significant impact on survival in breast cancer patients. However, in subgroup of patients treated with chemotherapy without anthracycline, the A2A2 genotype of the PIN3 (+16 bp) polymorphism was associated with poorer overall survival than other genotypes by Kaplan-Meier analysis (P = 0.048). The TP53 polymorphisms, Arg72Pro and PIN3 (+16 bp), had no impact on survival in unselected sporadic breast cancer patients in Croatian population. However, the results support the role of the A2A2 genotype of the PIN3 (+16 bp) polymorphism as a marker for identification of patients that may benefit from anthracycline-containing chemotherapy.
引用
收藏
页码：472 / 478
页数：7
相关论文
共 26 条
[1]   Activation and activities of the p53 tumour suppressor protein [J].
Bálint, É ;
Vousden, KH .
BRITISH JOURNAL OF CANCER, 2001, 85 (12) :1813-1823
[2]   p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis [J].
Bergamaschi, D ;
Gasco, M ;
Hiller, L ;
Sullivan, A ;
Syed, N ;
Trigiante, G ;
Yulug, I ;
Merlano, M ;
Numico, G ;
Comino, A ;
Attard, M ;
Reelfs, O ;
Gusterson, B ;
Bell, AK ;
Heath, V ;
Tavassoli, M ;
Farrell, PJ ;
Smith, P ;
Lu, X ;
Crook, T .
CANCER CELL, 2003, 3 (04) :387-402
[3]  
Bonafé M, 2003, CLIN CANCER RES, V9, P4860
[4]   Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer [J].
Costa, Sandra ;
Pinto, Daniela ;
Pereira, Deolinda ;
Rodrigues, Helena ;
Cameselle-Teijeiro, Jorge ;
Medeiros, Rui ;
Schmitt, Fernando .
BMC CANCER, 2008, 8 (1)
[5]   The codon 72 polymorphic variants of p53 have markedly different apoptotic potential [J].
Dumont, P ;
Leu, JIJ ;
Della Pietra, AC ;
George, DL ;
Murphy, M .
NATURE GENETICS, 2003, 33 (03) :357-365
[6]   A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA [J].
Gemignani, F ;
Moreno, V ;
Landi, S ;
Moullan, N ;
Chabrier, A ;
Gutiérrez-Enríquez, S ;
Hall, J ;
Guino, E ;
Peinado, MA ;
Capella, G ;
Canzian, F .
ONCOGENE, 2004, 23 (10) :1954-1956
[7]  
Goode EL, 2002, CANCER RES, V62, P3052
[8]  
Langerod A, 2002, CANCER EPIDEM BIOMAR, V11, P1684
[9]   Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women [J].
Noma, C ;
Miyoshi, Y ;
Taguchi, T ;
Tamaki, Y ;
Noguchi, S .
CANCER LETTERS, 2004, 210 (02) :197-203
[10]   The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer [J].
Olivier, M ;
Langerod, A ;
Carrieri, P ;
Bergh, J ;
Klaar, S ;
Eyfjord, J ;
Theillet, C ;
Rodriguez, C ;
Lidereau, R ;
Bièche, I ;
Varley, J ;
Bignon, Y ;
Uhrhammer, N ;
Winqvist, R ;
Jukkola-Vuorinen, A ;
Niederacher, D ;
Kato, S ;
Ishioka, C ;
Hainaut, P ;
Borresen-Dale, AL .
CLINICAL CANCER RESEARCH, 2006, 12 (04) :1157-1167
123